ArticleScientific reports2022
Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Mac-2 binding protein glycosylation isomer as a novel serum biomarker for recurrence in hepatocellular carcinoma.World journal of gastroenterology · 2026Pooled it
- Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective.Clinical and molecular hepatology · 2023Guideline
- Platelet count as a prognostic biomarker in resected hepatocellular carcinoma: differential impact of thrombocytosis and thrombocytopenia by btiology and fibrosis.Surgery today · 2026Article
- Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis.Liver cancer · 2026Article
- The global epidemiology of hepatocellular carcinoma.Hepatology communications · 2026Review
- Strategy for Hepatitis B and C Virus Testing Campaigns Through Web Services and Digital Advertising in Japan: Nationwide Cross-Sectional Study With Correspondence Analysis.Journal of medical Internet research · 2026Article
- Hepatocellular Carcinoma in the Eastern World: Screening, Diagnosis, Staging and Treatment.Current pharmaceutical design · 2026Review
- Disease burden and prediction of liver cancer attributable to metabolic risks in five East Asian countries from 1990 to 2023.PloS one · 2026Article
- Diagnosing and treating fatty liver disease: strategies for hepatocellular carcinoma and cardiovascular disease prevention.Clinical and experimental hepatology · 2025Article
- Relative survival among cancer survivors enrolled in private cancer insurance in Japan, using the internal insurance-enrolled population as the reference.International journal of clinical oncology · 2025Review
- Article
- Regional Difference of Liver Cancer in Japan: A Real-world Evidence Using the National Database of Health Insurance Claims.Internal medicine (Tokyo, Japan) · 2025Article
- First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial.Liver cancer · 2025Article
- Article
- Article
- Survey on Awareness and Implementation Rate of Ultrasound Elastography and Attenuation Imaging.Internal medicine (Tokyo, Japan) · 2025Article
- Low Intrahepatic Distant Recurrence Rate Following RFA Using Linear Mode in Patients With Hepatocellular Carcinoma.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Review
- Adipose-derived stem cells using fibrin gel as a scaffold enhances post-hepatectomy liver regeneration.Scientific reports · 2025Article
- Serum miRNA-101 expression signature as non-invasive diagnostic biomarker for Hepatitis C virus-associated hepatocellular carcinoma in Egyptian patients.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We examined the epidemiological trends, including the distribution of sex, age, and disease etiology, in HCC incident cases, over 24 years. Data of 20,547 HCC patients (1996-2019) were analyzed in this prospective study. We divided the study period into four 6-yearly quarters. HCC etiology was categorized as hepatitis B virus (HBV) infection, HBV + hepatitis C virus (HCV) infection, HCV infection, and both negative (non-BC). The incident cases of HCC per quarter of the study period were 4311 (21.0%), 5505 (26.8%), 5776 (28.1%), and 4955 (24.1%), sequentially. Overall, 14,020 (68.2%) patients were male. The number of HCC cases in patients < 60 years, 60-69 years, 70-79 years, and ≥ 80 years were 3711 (18.1%), 6652 (32.4%), 7448 (36.2%), and 2736 (13.3%), respectively. The average age of newly-diagnosed patients increased in each quarter. HCC was associated with HBV, HBV + HCV, and HCV infections and non-BC in 2997 (14.6%), 187 (0.9%), and 12,019 (58.5%), and 5344 (26.0%) cases, respectively. The number of HCV-associated cases decreased in each quarter, while that of non-BC-associated cases increased. HCC incident cases tend to increase in the elderly and in non-BC patients; in contrast, HCC incident cases due to HCV tend to decrease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.